Nassiri, Farshad http://orcid.org/0000-0002-0797-3425
Patil, Vikas
Yefet, Leeor S.
Singh, Olivia http://orcid.org/0000-0001-7321-6775
Liu, Jeff
Dang, Rachel M. A.
Yamaguchi, Takafumi N.
Daras, Mariza
Cloughesy, Timothy F. http://orcid.org/0000-0002-8656-7483
Colman, Howard
Kumthekar, Priya U.
Chen, Clark C. http://orcid.org/0000-0001-9544-2570
Aiken, Robert
Groves, Morris D.
Ong, Shirley S.
Ramakrishna, Rohan
Vogelbaum, Michael A.
Khagi, Simon
Kaley, Thomas
Melear, Jason M.
Peereboom, David M.
Rodriguez, Analiz
Yankelevich, Maxim
Nair, Suresh G.
Puduvalli, Vinay K.
Aldape, Kenneth http://orcid.org/0000-0001-5119-7550
Gao, Andrew
López-Janeiro, Álvaro
de Andrea, Carlos E.
Alonso, Marta M. http://orcid.org/0000-0002-7520-7351
Boutros, Paul http://orcid.org/0000-0003-0553-7520
Robbins, Joan
Mason, Warren P.
Sonabend, Adam M.
Stupp, Roger http://orcid.org/0000-0002-5483-3118
Fueyo, Juan
Gomez-Manzano, Candelaria http://orcid.org/0000-0002-1259-2133
Lang, Frederick F. http://orcid.org/0000-0003-3747-873X
Zadeh, Gelareh http://orcid.org/0000-0002-6637-4502
Article History
Received: 20 August 2022
Accepted: 12 April 2023
First Online: 15 May 2023
Competing interests
: A.M.S. has received in-kind (drug) support from BMS, in-kind (ultrasound devices) and research support from Carthera, and in-kind (drug) and research support from Agenus. A.R. is a Medexus consultant (paid), on the Nico Oncology Tissue Advisory Board (unpaid), and has an extramural grant from the Bristol Myers Squibb Diversity in Clinical Trials Program. C.C.C. is a consultant for Clearpoint Neuro and Medtronic, and receives travel reimbursement from GTMedical for lectures. C.G.-M. has license agreements with DNATrix, and is a shareholder of DNATrix. F.F.L. is a patent holder for DNX-2401. H.C. is on the advisory/consult for Best Doctors/Teladoc, Orbus Therapeutics, Bristol Meyers Squibb, Regeneron, Novocure Research Funding (Site PI/Institutional Contract): Newlink Genetics, Plexxikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, Forma Therapeutics, GCAR, Array BioPharma, Karyopharm Therapeutics, Nuvation Bio, Bayer, Bristol Meyers Squibb, Sumitomo Dainippon Pharma Oncology, Samus Therapeutics and Erasca. J.F. has license agreements with DNATrix, and is a shareholder of DNATrix. J.M.M. has been a speaker for AstraZeneca, Janssen and TG Therapeutics. J.R. is employed by DNATrix. M.A.V. is consulting/receives honoraria from Chimerix, Midatech and Olympus, their hospital has contracts with Infuseon, Oncosynergy, Celgene, Denovo, Chimerix and NIH, and has patent rights for Cleveland Clinic/Infuseon. M.M.A. has a research grant from DNATrix unrelated to this work. P.U.K. receives consulting fees from Enclear Therapies, Affinia Therapeutics, Biocept, Janssen, Sintetica, Bioclinica/Clario, Novocure, Mirati and Orbus Therapeutics, performs contracted research for Genentech, Novocure, DNAtrix and Orbus Therapeutics, is a scientific consultant for Enclear Therapies (with grant options provided) and has intellectual properties without financial gain of European Patent 3307327, 12 August 2020 and US Patent Pending 15/737,188. R.A. is a consultant for Tactical Therapeutics and Axelar AB. R.S. is a consultant and receives fees from Alpheus Medical, AstraZeneca, Carthera, Celularity, GT Medical, Insightec, Black Diamond, Northwest Therapeutics, Syneos Health (Boston Biomedical) and Varian Medical Systems, is a consultant and their institution receives fees from Boston Scientific, is a consultant and receives no fees from Novocure, is an IP holder for therapeutic ultrasound indications and use, is a Board Member and former president of the European Organisation for Research Treatment of Cancer, and has stock options in Alpheus Medical and Carthera. S.G.N. is an Institutional PI of multicenter trials with BMS, Merck, Strata Oncology and Mirati Therapeutics, and is the Chair of ABIM Med Onc Board. S.K. receives honorarium from Novocure, is reimbursed/has sponsored travel from Novocure, is consulting for Pacific Marine Biotech, Autem Therapeutics, and is management/holds a director position for SKBio Advisory, LLC. T.F.C. is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, holds stock for Erasca, is member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, is member of the scientific advisory board for Break Through Cancer, is member of the scientific advisory board for Cure Brain Cancer Foundation, and has provided paid consulting services to Blue Rock, Vida Ventures, Lista Therapeutics, Stemline, Novartis, Roche, Sonalasense, Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Novocure, Novogen, Boston Biomedical, Sunovion, Insys, Pfizer, Notable labs, Medqia, Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Roche, VBI, Merck, Novartis, BMS, AstraZeneca and Servier. The Regents of the University of California (T.F.C. employer) has licensed intellectual property co-invented by T.F.C. to Katmai Pharmaceuticals. V.K.P. receives clinical trial support from Servier, Karyopharm, Samus Therapeutics and Radiomedix, receives research support from Karyopharm, Bexion, SK Lifesciences and J INTS Bio, is a consultant for Servier, Insightec, Novocure, NewBio and Orbus Therapeutics, and has equity in Gilead and Amarin. W.P.M. is a consultant for Century Therapeutics, Ono Therapeutics and Novocure, and receives research funding from Hoffman La Roche, Agios and Orbus Therapeutics. The remaining authors declare no competing interests.